Novel antimicrobial target discovery by an integrated approach.

该项目旨在揭示BDM-I的分子靶标，BDM-I是澳大利亚初创公司BioDiem Ltd.发现的一种新型候选抗菌剂。BDM-I对许多耐药细菌和真菌微生物具有活性，目前正处于临床前开发阶段。然而，由于缺乏耐药表型，很难确定BDM-I的作用机制。该项目计划使用一种综合方法，将一种新的电子筛查技术与实验验证相结合。预计项目成果将包括第一个整合靶标和配基相似性的计算方法，用于蛋白质组规模的靶标和靶外发现，这将推动全球抗击耐药微生物的斗争。

The project aims to uncover the molecular targets of BDM-I, a novel antimicrobial candidate discovered by the start-up Australian company BioDiem Ltd. BDM-I is active against many drug resistant bacterial and fungal microorganisms and it is currently in pre-clinical development. However, the lack of resistant phenotypes makes it difficult to identify BDM-I’s mechanism of action. The project plans to use an integrated approach that combines a novel technique of in silico screening with experimental validation. Project outcomes are anticipated to include the first computational method to integrate target and ligand similarity for proteome-scale target and off-target discovery, which will advance the global fight against drug-resistant microorganisms.